Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer-Reference-Cited by-同舟云学术

Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer

Published:2014-03-05 Issue:1 Volume:7 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Thalgott Mark,Horn Thomas,Heck Matthias M,Maurer Tobias,Eiber Matthias,Retz Margitta,Autenrieth Michael,Herkommer Kathleen,Krause Bernd J,Gschwend Jürgen E,Treiber Uwe,Kübler Hubert R

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/1756-8722-7-20.pdf

Reference30 articles.

1. Kattan MW, Eastham JA, Stapleton AMF, Wheeler TM, Scardino PT: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998, 90: 766-771. 10.1093/jnci/90.10.766.

2. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998, 280 (11): 969-974. 10.1001/jama.280.11.969.

3. Sonpavde G, Sternberg CN: Neoadjuvant systemic therapy for urological malignancies. BJU Int. 2010, 106 (1): 6-22.

4. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002, 360 (9327): 103-106. 10.1016/S0140-6736(02)09408-4.

5. Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W, NCIC CTG, PR.3/MRC UK PR07 investigators: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011, 378 (9809): 2104-2111. 10.1016/S0140-6736(11)61095-7.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials;Frontiers in Pharmacology;2023-06-26

2. Combined treatment of high and very high risk prostate cancer: results of neoadjuvant treatment;Research and Practical Medicine Journal;2023-05-18

3. Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study;European Journal of Nuclear Medicine and Molecular Imaging;2022-11-22

4. Neoadjuvant Systemic Therapy Prior to Radical Prostatectomy for Clinically Localized High-Risk Prostate Cancer;Frontiers in Urology;2022-03-10

5. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer;Nature Reviews Urology;2021-09-15